Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 16, 2022 08:00 ET | Source: Entera Bio Ltd.

Entera Bio Board Member, Miranda Toledano, to Assume Role of Chief Business Officer, Chief Financial Officer, and Head of Corporate Strategy

BOSTON and JERUSALEM, May 16, 2022 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered large molecule therapeutics, today announced the appointment of...
May 12, 2022 08:00 ET | Source: Entera Bio Ltd.

Entera Bio Reports First Quarter 2022 Financial Results and Business Highlights

Registrational study design for lead clinical asset, EB613, as the first oral PTH anabolic to treat post-menopausal women at high risk of osteoporosis, is underwayCompany reschedules conference call...
May 05, 2022 08:00 ET | Source: Entera Bio Ltd.

Entera Bio Files Patent Applications for Inventions that Optimize its Platform Technology for Oral Delivery of Large Molecule Therapeutics

— Inventions aim to improve bioavailability and reduce drug costs — — Patent applications include optimized oral delivery of specific molecules for various indications — BOSTON and JERUSALEM, May ...
April 28, 2022 08:00 ET | Source: Entera Bio Ltd.

Entera Bio to Report First Quarter 2022 Financial Results on May 12

BOSTON and JERUSALEM, April 28, 2022 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered large molecule therapeutics, announced today it will report...
March 22, 2022 08:00 ET | Source: Entera Bio Ltd.

Entera Bio to Present at 2022 Maxim Virtual Growth Conference

BOSTON and JERUSALEM, March 22, 2022 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered large molecule therapeutics, today announced that the Company...
March 08, 2022 06:30 ET | Source: Entera Bio Ltd.

Entera Bio Reports Financial Results for the Year Ended December 31, 2021

— EB613 expected to commence pivotal Phase 3 Osteoporosis trial in 2022 —— New EB612 formulation for Hypoparathyroidism trial planned in 2022 —— Oral delivery technology platform advances with more...
March 03, 2022 09:50 ET | Source: Entera Bio Ltd.

Entera Bio to Report Business and Financial Results for the Year Ended December 31, 2021 on March 8, 2022

BOSTON and JERUSALEM, March 03, 2022 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered large molecule therapeutics, announced today it will report...
February 17, 2022 08:30 ET | Source: Entera Bio Ltd.

Entera Bio to Present at Aegis Virtual Conference on February 23rd

BOSTON and JERUSALEM, Israel, Feb. 17, 2022 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered large molecule therapeutics, today announced that the...
January 04, 2022 08:30 ET | Source: Entera Bio Ltd.

Entera Bio Announces Successful EB613 End-of-Phase 2 Meeting with FDA: FDA Agrees to Phase 3 Twelve Month Study with Lumbar Spine BMD (bone mineral density) as the Primary Endpoint

BOSTON and JERUSALEM, Israel, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), today announced it has concluded its End-of-Phase 2 meeting with the U.S. Food and Drug...
November 10, 2021 08:30 ET | Source: Entera Bio Ltd.

Entera Bio Reports Third Quarter 2021 Financial Results

‒ Two Presentations at ASBMR, including Late Breaker, on Phase 2 EB613 Clinical Trial Results in Osteoporosis ‒ ‒ Study Sets Stage for Phase 3 registrational trial in 2022 ‒ BOSTON and...